Changes in Hong Kong stocks | Keji Pharmaceutical-B (02171) rose more than 7% CT071 research results will soon be presented at the EHA annual meeting CT041 is expected to submit an NDA in the first half of the year

Zhitongcaijing · 05/09 07:25

The Zhitong Finance App learned that Keji Pharmaceutical-B (02171) rose by more than 7%. As of press release, it had risen 7.49% to HK$16.64, with a turnover of HK$25.4024 million.

According to the news, Keji Pharmaceutical previously announced that the summary results of the CT071 (an autologous CAR-T cell product targeting GPRC5D) clinical trial (NCT06407947) initiated by researchers to treat newly diagnosed multiple myeloma (NDMM) has been accepted by the 2025 European Hematology Association (EHA) Annual Meeting and will be published during the poster presentation session. The summary and further information will be published after 15:30 CET on May 14, 2025.

Furthermore, the company announced that a summary of the findings of the confirmed phase II clinical trials (CT041-ST-01, NCT04581473) for advanced gastric cancer/esophagastric junction adenocarcinoma conducted in China (product number: CT041,, an autologous CAR-T cell therapy candidate product targeting Claudin18.2 protein) was accepted for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The summary and further information will be announced after May 22, 2025 EST. Zheshang Securities previously stated that according to the company's annual report, it is expected to submit an NDA for advanced treatment of GC/GEJ indications in 2025H1, and the bank believes it is expected to be the first solid tumor CAR-T drug approved for commercialization. Considering the large base of patients with solid tumors, I am optimistic about the commercialization prospects of CT041.